EPO and acute kidney injury: A more recent and larger (n = 162) study (EARLYARF trial) assessed EPO's effect in ICU patients deemed at risk for AKI (defined by a specific cutoff value of two proximal tubular enzymes in urine: γ-glutamyl transpeptidase [GGT] and alkaline phosphatase [ALP]) (Table 3) [57].